Julien Mazieres/X
Mar 28, 2025, 19:38
Julien Mazieres: Another brick in the wall of HER2-mutant NSCLC
Julien Mazieres, Coordinator of the Transversal Federation of Oncology at CHU of Toulouse, shared on X:
“Another brick in the wall of HER2 mut NSCLC. Promising efficacy of BAY in HER2 naive pts (ORR 70.5%) but also in pts treated with TDxD (ORR 35.3%). Diarrhea as the most frequent AE (almost all pts but no tt discontinuation).”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 20, 2025, 14:56
Apr 20, 2025, 14:07
Apr 20, 2025, 13:49
Apr 20, 2025, 13:31